Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2005-12

AUTHORS

Rodney J. Hicks, Danny Rischin, Richard Fisher, David Binns, Andrew M. Scott, Lester J. Peters

ABSTRACT

PURPOSE: The purpose of the study was to evaluate [(18)F]fluoromisonidazole (FMISO) PET in advanced head and neck cancer during hypoxia-targeting therapy. METHODS: Fifteen of 16 patients in a phase I trial of chemoradiation plus tirapazamine (specific cytotoxin for hypoxic cells) in advanced (T3/4 and/or N2/3) head and neck cancer underwent serial [(18)F]fluorodeoxyglucose (FDG) and FMISO PET. We have previously reported excellent early clinical outcome of these patients and now review FMISO PET results in the context of longer follow-up of this patient cohort. RESULTS: Based on blinded qualitative scoring by two readers, FMISO PET was positive in 13/15 patients at baseline: 12/15 of primary sites and 8/13 neck nodes were scored as positive. All sites of corresponding FDG and FMISO abnormality at baseline showed marked qualitative reduction of uptake within 4 weeks of commencing therapy, consistent with effective hypoxia-targeted therapy. With a median follow-up of 6.9 years, there have been only four locoregional failures, while three other patients have died of metachronous lung cancer. The 5-year overall survival was 50% (95% CI 27-73%), the 5-year failure-free survival was 44% (95% CI 22-68%) and the 5-year freedom from locoregional failure was 68% (95% CI 38-88%). CONCLUSION: The high prevalence of hypoxia demonstrated on FMISO PET imaging is consistent with the advanced disease stage of these patients and would be expected to predict an adverse prognosis. Evidence of the early resolution of FMISO abnormality during treatment, associated with excellent locoregional control in this patient cohort, supports further investigation of hypoxia-targeting agents in advanced head and neck cancer. More... »

PAGES

1384-1391

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00259-005-1880-2

DOI

http://dx.doi.org/10.1007/s00259-005-1880-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1000500683

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/16133382


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Benzylamines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Squamous Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Hypoxia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chemotherapy, Adjuvant", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cisplatin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cohort Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Delivery Systems", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Head and Neck Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Positron-Emission Tomography", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Radiation-Sensitizing Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Radiopharmaceuticals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Reproducibility of Results", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sensitivity and Specificity", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Single-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tirapazamine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Triazines", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Melbourne", 
          "id": "https://www.grid.ac/institutes/grid.1008.9", 
          "name": [
            "Centre for Molecular Imaging, Peter MacCallum Cancer Centre, Locked Bag No 1, A\u2019Beckett St., 8006, Melbourne, Australia", 
            "Department of Medicine, St Vincent\u2019s Medical School, University of Melbourne, Melbourne, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hicks", 
        "givenName": "Rodney J.", 
        "id": "sg:person.01121233254.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01121233254.97"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Peter MacCallum Cancer Centre", 
          "id": "https://www.grid.ac/institutes/grid.1055.1", 
          "name": [
            "Department of Medicine, St Vincent\u2019s Medical School, University of Melbourne, Melbourne, Australia", 
            "Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rischin", 
        "givenName": "Danny", 
        "id": "sg:person.01270354677.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01270354677.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Peter MacCallum Cancer Centre", 
          "id": "https://www.grid.ac/institutes/grid.1055.1", 
          "name": [
            "Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fisher", 
        "givenName": "Richard", 
        "id": "sg:person.0636322277.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636322277.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Peter MacCallum Cancer Centre", 
          "id": "https://www.grid.ac/institutes/grid.1055.1", 
          "name": [
            "Centre for Molecular Imaging, Peter MacCallum Cancer Centre, Locked Bag No 1, A\u2019Beckett St., 8006, Melbourne, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Binns", 
        "givenName": "David", 
        "id": "sg:person.01213140513.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01213140513.69"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Austin Hospital", 
          "id": "https://www.grid.ac/institutes/grid.414094.c", 
          "name": [
            "Centre for PET, and Ludwig Institute for Cancer Research, Austin Hospital, Melbourne, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Scott", 
        "givenName": "Andrew M.", 
        "id": "sg:person.010717270007.67", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010717270007.67"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Peter MacCallum Cancer Centre", 
          "id": "https://www.grid.ac/institutes/grid.1055.1", 
          "name": [
            "Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Peters", 
        "givenName": "Lester J.", 
        "id": "sg:person.01302113573.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01302113573.05"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/s0167-8140(96)91811-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001061212"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0360-3016(88)90002-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004522248"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0167-8140(00)00223-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006927632"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0304-3835(03)00012-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013725216"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0304-3835(03)00012-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013725216"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1993.220", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014932976", 
          "https://doi.org/10.1038/bjc.1993.220"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1993.220", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014932976", 
          "https://doi.org/10.1038/bjc.1993.220"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0360-3016(00)00467-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016204459"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/978-94-017-1828-8_6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018024415", 
          "https://doi.org/10.1007/978-94-017-1828-8_6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(00)90011-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028182366"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0360-3016(01)01477-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031488052"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0360-3016(97)00101-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035454754"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1535-6108(03)00085-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044383357"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0360-3016(96)00325-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050726937"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1259/0007-1285-26-312-638", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064544114"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074508163", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2001.19.2.535", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074768342"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077003947", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078552776", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082791815", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2005-12", 
    "datePublishedReg": "2005-12-01", 
    "description": "PURPOSE: The purpose of the study was to evaluate [(18)F]fluoromisonidazole (FMISO) PET in advanced head and neck cancer during hypoxia-targeting therapy.\nMETHODS: Fifteen of 16 patients in a phase I trial of chemoradiation plus tirapazamine (specific cytotoxin for hypoxic cells) in advanced (T3/4 and/or N2/3) head and neck cancer underwent serial [(18)F]fluorodeoxyglucose (FDG) and FMISO PET. We have previously reported excellent early clinical outcome of these patients and now review FMISO PET results in the context of longer follow-up of this patient cohort.\nRESULTS: Based on blinded qualitative scoring by two readers, FMISO PET was positive in 13/15 patients at baseline: 12/15 of primary sites and 8/13 neck nodes were scored as positive. All sites of corresponding FDG and FMISO abnormality at baseline showed marked qualitative reduction of uptake within 4 weeks of commencing therapy, consistent with effective hypoxia-targeted therapy. With a median follow-up of 6.9 years, there have been only four locoregional failures, while three other patients have died of metachronous lung cancer. The 5-year overall survival was 50% (95% CI 27-73%), the 5-year failure-free survival was 44% (95% CI 22-68%) and the 5-year freedom from locoregional failure was 68% (95% CI 38-88%).\nCONCLUSION: The high prevalence of hypoxia demonstrated on FMISO PET imaging is consistent with the advanced disease stage of these patients and would be expected to predict an adverse prognosis. Evidence of the early resolution of FMISO abnormality during treatment, associated with excellent locoregional control in this patient cohort, supports further investigation of hypoxia-targeting agents in advanced head and neck cancer.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00259-005-1880-2", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1297401", 
        "issn": [
          "1619-7070", 
          "1619-7089"
        ], 
        "name": "European Journal of Nuclear Medicine and Molecular Imaging", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "12", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "32"
      }
    ], 
    "name": "Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent", 
    "pagination": "1384-1391", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "026203cea12fe3d8d3475ddce76b04a326197bbc63fc331da426bdc993fd4003"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "16133382"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101140988"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00259-005-1880-2"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1000500683"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00259-005-1880-2", 
      "https://app.dimensions.ai/details/publication/pub.1000500683"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T12:04", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000360_0000000360/records_118312_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs00259-005-1880-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00259-005-1880-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00259-005-1880-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00259-005-1880-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00259-005-1880-2'


 

This table displays all metadata directly associated to this object as RDF triples.

271 TRIPLES      21 PREDICATES      73 URIs      47 LITERALS      35 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00259-005-1880-2 schema:about N02f8833df3fe4ad9b967b19c5eddf304
2 N07f5bdf9b25540b2872fa00420b76c26
3 N0bc0c6661a95420caa4e67b05d224439
4 N0c487356f45a416fb76a8ddda566aea4
5 N1bc00f3889064bcab5979062ae5ae13b
6 N2590fc19adaa40759cd27c4de3bd688f
7 N343ab4a3fe32450e999a105e8cb89c0d
8 N388c1700b83b41a8877629e437cde14b
9 N3c7269a2c5fd439ca2e6a5a9501e5f8b
10 N5097354439b441349745432b471fd7e1
11 N5b24b82cf7e648d79a83dcc41f30c1ea
12 N636daad1d3d14150985bfd3f358a8548
13 N71d824dc6a8c4f17bae9dc440e341020
14 N7829860803674c96b7a6b9ced16bd6de
15 Na28102ff65bd4220bf3e1f1b7bf1d730
16 Na7f71ba9ac484ac4b2e3727e9f210691
17 Nb1439d04d6ca4515bafce94886bf90c1
18 Nb549a0a6fb0e429da0536085a0400566
19 Nc175e6aa287543789d3baccceaeb58f3
20 Nc706a89d95734d0aafa260fac7ac7a38
21 Ncac9e3cd6ee14b279c7cdc7b5e75d382
22 Ne9a658b8ad2e4861ab48b326b7e98d9f
23 Neb93a279d9ca4c8da75f2f58fd19a289
24 Nebfaa75fde784cbcba7a066f30e017af
25 Nfb6f7bc98aeb40239b9ced1bf57c0bf0
26 Nfec6c6ef6f8645679232806a95eed211
27 anzsrc-for:11
28 anzsrc-for:1112
29 schema:author N8c6f8b4e073649a2a2f17ccd5a95595c
30 schema:citation sg:pub.10.1007/978-94-017-1828-8_6
31 sg:pub.10.1038/bjc.1993.220
32 https://app.dimensions.ai/details/publication/pub.1074508163
33 https://app.dimensions.ai/details/publication/pub.1077003947
34 https://app.dimensions.ai/details/publication/pub.1078552776
35 https://app.dimensions.ai/details/publication/pub.1082791815
36 https://doi.org/10.1016/0360-3016(88)90002-8
37 https://doi.org/10.1016/s0140-6736(00)90011-4
38 https://doi.org/10.1016/s0167-8140(00)00223-1
39 https://doi.org/10.1016/s0167-8140(96)91811-3
40 https://doi.org/10.1016/s0304-3835(03)00012-0
41 https://doi.org/10.1016/s0360-3016(00)00467-3
42 https://doi.org/10.1016/s0360-3016(01)01477-8
43 https://doi.org/10.1016/s0360-3016(96)00325-2
44 https://doi.org/10.1016/s0360-3016(97)00101-6
45 https://doi.org/10.1016/s1535-6108(03)00085-0
46 https://doi.org/10.1200/jco.2001.19.2.535
47 https://doi.org/10.1259/0007-1285-26-312-638
48 schema:datePublished 2005-12
49 schema:datePublishedReg 2005-12-01
50 schema:description PURPOSE: The purpose of the study was to evaluate [(18)F]fluoromisonidazole (FMISO) PET in advanced head and neck cancer during hypoxia-targeting therapy. METHODS: Fifteen of 16 patients in a phase I trial of chemoradiation plus tirapazamine (specific cytotoxin for hypoxic cells) in advanced (T3/4 and/or N2/3) head and neck cancer underwent serial [(18)F]fluorodeoxyglucose (FDG) and FMISO PET. We have previously reported excellent early clinical outcome of these patients and now review FMISO PET results in the context of longer follow-up of this patient cohort. RESULTS: Based on blinded qualitative scoring by two readers, FMISO PET was positive in 13/15 patients at baseline: 12/15 of primary sites and 8/13 neck nodes were scored as positive. All sites of corresponding FDG and FMISO abnormality at baseline showed marked qualitative reduction of uptake within 4 weeks of commencing therapy, consistent with effective hypoxia-targeted therapy. With a median follow-up of 6.9 years, there have been only four locoregional failures, while three other patients have died of metachronous lung cancer. The 5-year overall survival was 50% (95% CI 27-73%), the 5-year failure-free survival was 44% (95% CI 22-68%) and the 5-year freedom from locoregional failure was 68% (95% CI 38-88%). CONCLUSION: The high prevalence of hypoxia demonstrated on FMISO PET imaging is consistent with the advanced disease stage of these patients and would be expected to predict an adverse prognosis. Evidence of the early resolution of FMISO abnormality during treatment, associated with excellent locoregional control in this patient cohort, supports further investigation of hypoxia-targeting agents in advanced head and neck cancer.
51 schema:genre research_article
52 schema:inLanguage en
53 schema:isAccessibleForFree false
54 schema:isPartOf N54cf3531c19649f182cecc8c953769dd
55 N5e503130fc6149a3aa692bd68a4a6f47
56 sg:journal.1297401
57 schema:name Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent
58 schema:pagination 1384-1391
59 schema:productId Nc531821d75104066abc10587abf816ff
60 Nd2704813caa04235a12a5f347cecad52
61 Ndab1b5991bfe4d2192293d6026b5556f
62 Ne26522f497ab437e806bf3a45f07d61c
63 Ne7ffab71f6ad413887e50c1589635bca
64 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000500683
65 https://doi.org/10.1007/s00259-005-1880-2
66 schema:sdDatePublished 2019-04-11T12:04
67 schema:sdLicense https://scigraph.springernature.com/explorer/license/
68 schema:sdPublisher N72c4cb1f4af04b90936ff97c95cb16f3
69 schema:url http://link.springer.com/10.1007%2Fs00259-005-1880-2
70 sgo:license sg:explorer/license/
71 sgo:sdDataset articles
72 rdf:type schema:ScholarlyArticle
73 N02f8833df3fe4ad9b967b19c5eddf304 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
74 schema:name Single-Blind Method
75 rdf:type schema:DefinedTerm
76 N07f5bdf9b25540b2872fa00420b76c26 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Aged
78 rdf:type schema:DefinedTerm
79 N0bc0c6661a95420caa4e67b05d224439 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
80 schema:name Drug Delivery Systems
81 rdf:type schema:DefinedTerm
82 N0c487356f45a416fb76a8ddda566aea4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Radiation-Sensitizing Agents
84 rdf:type schema:DefinedTerm
85 N1bc00f3889064bcab5979062ae5ae13b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Radiopharmaceuticals
87 rdf:type schema:DefinedTerm
88 N2590fc19adaa40759cd27c4de3bd688f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Antineoplastic Combined Chemotherapy Protocols
90 rdf:type schema:DefinedTerm
91 N343ab4a3fe32450e999a105e8cb89c0d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Humans
93 rdf:type schema:DefinedTerm
94 N388c1700b83b41a8877629e437cde14b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Triazines
96 rdf:type schema:DefinedTerm
97 N3c7269a2c5fd439ca2e6a5a9501e5f8b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Positron-Emission Tomography
99 rdf:type schema:DefinedTerm
100 N46ec215525cf4e80b38717438ef87416 rdf:first sg:person.01270354677.50
101 rdf:rest N957a88daf9614bf79f3878d996424f8e
102 N5097354439b441349745432b471fd7e1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Tirapazamine
104 rdf:type schema:DefinedTerm
105 N54cf3531c19649f182cecc8c953769dd schema:issueNumber 12
106 rdf:type schema:PublicationIssue
107 N5b24b82cf7e648d79a83dcc41f30c1ea schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Benzylamines
109 rdf:type schema:DefinedTerm
110 N5e503130fc6149a3aa692bd68a4a6f47 schema:volumeNumber 32
111 rdf:type schema:PublicationVolume
112 N636daad1d3d14150985bfd3f358a8548 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Reproducibility of Results
114 rdf:type schema:DefinedTerm
115 N6b4e6539420949a68cce36e18d2a43b1 rdf:first sg:person.010717270007.67
116 rdf:rest Nf10af8c99fae4a7ebc4e26104ec607e3
117 N71d824dc6a8c4f17bae9dc440e341020 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Middle Aged
119 rdf:type schema:DefinedTerm
120 N72c4cb1f4af04b90936ff97c95cb16f3 schema:name Springer Nature - SN SciGraph project
121 rdf:type schema:Organization
122 N7829860803674c96b7a6b9ced16bd6de schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Female
124 rdf:type schema:DefinedTerm
125 N8c6f8b4e073649a2a2f17ccd5a95595c rdf:first sg:person.01121233254.97
126 rdf:rest N46ec215525cf4e80b38717438ef87416
127 N957a88daf9614bf79f3878d996424f8e rdf:first sg:person.0636322277.42
128 rdf:rest Nd92bec1e409f48e2bc4263523f21d79c
129 Na28102ff65bd4220bf3e1f1b7bf1d730 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Follow-Up Studies
131 rdf:type schema:DefinedTerm
132 Na7f71ba9ac484ac4b2e3727e9f210691 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Carcinoma, Squamous Cell
134 rdf:type schema:DefinedTerm
135 Nb1439d04d6ca4515bafce94886bf90c1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Head and Neck Neoplasms
137 rdf:type schema:DefinedTerm
138 Nb549a0a6fb0e429da0536085a0400566 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Cohort Studies
140 rdf:type schema:DefinedTerm
141 Nc175e6aa287543789d3baccceaeb58f3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Treatment Outcome
143 rdf:type schema:DefinedTerm
144 Nc531821d75104066abc10587abf816ff schema:name dimensions_id
145 schema:value pub.1000500683
146 rdf:type schema:PropertyValue
147 Nc706a89d95734d0aafa260fac7ac7a38 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Cisplatin
149 rdf:type schema:DefinedTerm
150 Ncac9e3cd6ee14b279c7cdc7b5e75d382 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Cell Hypoxia
152 rdf:type schema:DefinedTerm
153 Nd2704813caa04235a12a5f347cecad52 schema:name readcube_id
154 schema:value 026203cea12fe3d8d3475ddce76b04a326197bbc63fc331da426bdc993fd4003
155 rdf:type schema:PropertyValue
156 Nd92bec1e409f48e2bc4263523f21d79c rdf:first sg:person.01213140513.69
157 rdf:rest N6b4e6539420949a68cce36e18d2a43b1
158 Ndab1b5991bfe4d2192293d6026b5556f schema:name nlm_unique_id
159 schema:value 101140988
160 rdf:type schema:PropertyValue
161 Ne26522f497ab437e806bf3a45f07d61c schema:name pubmed_id
162 schema:value 16133382
163 rdf:type schema:PropertyValue
164 Ne7ffab71f6ad413887e50c1589635bca schema:name doi
165 schema:value 10.1007/s00259-005-1880-2
166 rdf:type schema:PropertyValue
167 Ne9a658b8ad2e4861ab48b326b7e98d9f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Chemotherapy, Adjuvant
169 rdf:type schema:DefinedTerm
170 Neb93a279d9ca4c8da75f2f58fd19a289 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Prognosis
172 rdf:type schema:DefinedTerm
173 Nebfaa75fde784cbcba7a066f30e017af schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Sensitivity and Specificity
175 rdf:type schema:DefinedTerm
176 Nf10af8c99fae4a7ebc4e26104ec607e3 rdf:first sg:person.01302113573.05
177 rdf:rest rdf:nil
178 Nfb6f7bc98aeb40239b9ced1bf57c0bf0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Adult
180 rdf:type schema:DefinedTerm
181 Nfec6c6ef6f8645679232806a95eed211 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Male
183 rdf:type schema:DefinedTerm
184 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
185 schema:name Medical and Health Sciences
186 rdf:type schema:DefinedTerm
187 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
188 schema:name Oncology and Carcinogenesis
189 rdf:type schema:DefinedTerm
190 sg:journal.1297401 schema:issn 1619-7070
191 1619-7089
192 schema:name European Journal of Nuclear Medicine and Molecular Imaging
193 rdf:type schema:Periodical
194 sg:person.010717270007.67 schema:affiliation https://www.grid.ac/institutes/grid.414094.c
195 schema:familyName Scott
196 schema:givenName Andrew M.
197 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010717270007.67
198 rdf:type schema:Person
199 sg:person.01121233254.97 schema:affiliation https://www.grid.ac/institutes/grid.1008.9
200 schema:familyName Hicks
201 schema:givenName Rodney J.
202 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01121233254.97
203 rdf:type schema:Person
204 sg:person.01213140513.69 schema:affiliation https://www.grid.ac/institutes/grid.1055.1
205 schema:familyName Binns
206 schema:givenName David
207 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01213140513.69
208 rdf:type schema:Person
209 sg:person.01270354677.50 schema:affiliation https://www.grid.ac/institutes/grid.1055.1
210 schema:familyName Rischin
211 schema:givenName Danny
212 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01270354677.50
213 rdf:type schema:Person
214 sg:person.01302113573.05 schema:affiliation https://www.grid.ac/institutes/grid.1055.1
215 schema:familyName Peters
216 schema:givenName Lester J.
217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01302113573.05
218 rdf:type schema:Person
219 sg:person.0636322277.42 schema:affiliation https://www.grid.ac/institutes/grid.1055.1
220 schema:familyName Fisher
221 schema:givenName Richard
222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636322277.42
223 rdf:type schema:Person
224 sg:pub.10.1007/978-94-017-1828-8_6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018024415
225 https://doi.org/10.1007/978-94-017-1828-8_6
226 rdf:type schema:CreativeWork
227 sg:pub.10.1038/bjc.1993.220 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014932976
228 https://doi.org/10.1038/bjc.1993.220
229 rdf:type schema:CreativeWork
230 https://app.dimensions.ai/details/publication/pub.1074508163 schema:CreativeWork
231 https://app.dimensions.ai/details/publication/pub.1077003947 schema:CreativeWork
232 https://app.dimensions.ai/details/publication/pub.1078552776 schema:CreativeWork
233 https://app.dimensions.ai/details/publication/pub.1082791815 schema:CreativeWork
234 https://doi.org/10.1016/0360-3016(88)90002-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004522248
235 rdf:type schema:CreativeWork
236 https://doi.org/10.1016/s0140-6736(00)90011-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028182366
237 rdf:type schema:CreativeWork
238 https://doi.org/10.1016/s0167-8140(00)00223-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006927632
239 rdf:type schema:CreativeWork
240 https://doi.org/10.1016/s0167-8140(96)91811-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001061212
241 rdf:type schema:CreativeWork
242 https://doi.org/10.1016/s0304-3835(03)00012-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013725216
243 rdf:type schema:CreativeWork
244 https://doi.org/10.1016/s0360-3016(00)00467-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016204459
245 rdf:type schema:CreativeWork
246 https://doi.org/10.1016/s0360-3016(01)01477-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031488052
247 rdf:type schema:CreativeWork
248 https://doi.org/10.1016/s0360-3016(96)00325-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050726937
249 rdf:type schema:CreativeWork
250 https://doi.org/10.1016/s0360-3016(97)00101-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035454754
251 rdf:type schema:CreativeWork
252 https://doi.org/10.1016/s1535-6108(03)00085-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044383357
253 rdf:type schema:CreativeWork
254 https://doi.org/10.1200/jco.2001.19.2.535 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074768342
255 rdf:type schema:CreativeWork
256 https://doi.org/10.1259/0007-1285-26-312-638 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064544114
257 rdf:type schema:CreativeWork
258 https://www.grid.ac/institutes/grid.1008.9 schema:alternateName University of Melbourne
259 schema:name Centre for Molecular Imaging, Peter MacCallum Cancer Centre, Locked Bag No 1, A’Beckett St., 8006, Melbourne, Australia
260 Department of Medicine, St Vincent’s Medical School, University of Melbourne, Melbourne, Australia
261 rdf:type schema:Organization
262 https://www.grid.ac/institutes/grid.1055.1 schema:alternateName Peter MacCallum Cancer Centre
263 schema:name Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, Australia
264 Centre for Molecular Imaging, Peter MacCallum Cancer Centre, Locked Bag No 1, A’Beckett St., 8006, Melbourne, Australia
265 Department of Medicine, St Vincent’s Medical School, University of Melbourne, Melbourne, Australia
266 Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
267 Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
268 rdf:type schema:Organization
269 https://www.grid.ac/institutes/grid.414094.c schema:alternateName Austin Hospital
270 schema:name Centre for PET, and Ludwig Institute for Cancer Research, Austin Hospital, Melbourne, Australia
271 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...